

RESEARCH

Open Access



Circulating dipeptidyl peptidase-3 at admission is associated with circulatory failure, acute kidney injury and death in severely ill burn patients

François Dépret^{1,2,3}, Juliette Amzallag¹, Adrien Pollina¹, Laure Fayolle-Pivot⁴, Maxime Coutrot^{1,2}, Maïté Chaussard¹, Karine Santos⁵, Oliver Hartmann⁵, Marion Jully¹, Alexandre Fratani¹, Haikel Oueslati¹, Alexandru Cupaciu¹, Mourad Benyamina^{1,2}, Lucie Guillemet¹, Benjamin Deniau^{1,2,3}, Alexandre Mebazaa^{1,2,3}, Etienne Gayat^{1,2,3}, Boris Farny^{4,6}, Julien Textoris^{4,6}, Matthieu Legrand^{1,2,3,7*} and for the PRONOBURN group

Abstract

Background: Dipeptidyl peptidase-3 (DPP3) is a metallopeptidase which cleaves bioactive peptides, notably angiotensin II, and is involved in inflammation regulation. DPP3 has been proposed to be a myocardial depressant factor and to be involved in circulatory failure in acute illnesses, possibly due to angiotensin II cleavage. In this study, we evaluated the association between plasmatic DPP3 level and outcome (mortality and hemodynamic failure) in severely ill burn patients.

Methods: In this biomarker analysis of a prospective cohort study, we included severely ill adult burn patients in two tertiary burn intensive care units. DPP3 was measured at admission ($\text{DPP3}_{\text{admin}}$) and 3 days after. The primary endpoint was 90-day mortality. Secondary endpoints were hemodynamic failure and acute kidney injury (AKI).

Results: One hundred and eleven consecutive patients were enrolled. The median age was 48 (32.5–63) years, with a median total body surface area burned of 35% (25–53.5) and Abbreviated Burn Severity Index (ABSI) of 8 (7–11). Ninety-day mortality was 32%. The median $\text{DPP3}_{\text{admin}}$ was significantly higher in non-survivors versus survivors (53.3 ng/mL [IQR 28.8–103.5] versus 27.1 ng/mL [IQR 19.4–38.9]; $p < 0.0001$). Patients with a sustained elevated DPP3 had an increased risk of death compared to patients with high $\text{DPP3}_{\text{admin}}$ but decreased levels on day 3. Patients with circulatory failure had higher $\text{DPP3}_{\text{admin}}$ (39.2 ng/mL [IQR 25.9–76.1] versus 28.4 ng/mL [IQR 19.8–39.6]; $p = 0.001$) as well as patients with AKI (49.7 ng/mL [IQR 30.3–87.3] versus 27.6 ng/mL [IQR 19.4–41.4]; $p = 0.001$). $\text{DPP3}_{\text{admin}}$ added prognostic value on top of ABSI (added χ^2 12.2, $p = 0.0005$), Sequential Organ Failure Assessment (SOFA) score at admission (added χ^2 4.9, $p = 0.0268$), and plasma lactate at admission (added χ^2 6.9, $p = 0.0086$) to predict circulatory failure within the first 48 h.

(Continued on next page)

* Correspondence: matthieu.legrand@ucsf.edu

¹Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, GH St-Louis-Lariboisière, Paris, France

²University Paris Diderot, Paris, France

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

Conclusions: Plasma DPP3 concentration at admission was associated with an increased risk of death, circulatory failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.

Keywords: Dipeptidyl peptidase-3, Burn patients, Mortality, Acute kidney injury, Biomarkers

Background

Severe burn injury is associated with an early and profound hypovolemia followed by an intense systemic inflammatory response. Hemodynamic management, including fluid resuscitation, has long been recognized as the cornerstone of the early management and hemodynamic resuscitation of severely burned patients [1–3]. However, a systemic inflammatory response may be associated with distributive shock and/or acute myocardial dysfunction [4]. Dipeptidyl peptidase-3 (DPP3), also named enkephalinase B or red cell angiotensinase, is a predominantly intracellular, ubiquitously expressed, zinc-dependent metallopeptidase involved in the metabolism of peptides [5] implicated in many different pathways (e.g., blood pressure regulation, inflammation). DPP3 cleaves bioactive peptides, notably angiotensin II, enkephalins, and endorphins [6–8]. We hypothesize that cleavage of angiotensin II by DPP3 may promote vasodilatation and circulatory failure. Severe burn patients are at high risk of developing vasodilatory shock with systemic inflammatory response after the early phase of hypovolemic shock. The main objective of this study was therefore to assess the association between DPP3 at admission ($DPP3_{\text{admin}}$) and day 3 ($DPP3_{\text{Day3}}$) with 90-day mortality in severely burned patients. The secondary objective was to evaluate the association between DPP3 and organ dysfunction (i.e., circulatory failure and acute kidney injury (AKI)).

Methods

Study design and population

We conducted a double-center cohort study in the Burn Unit of Saint Louis Hospital (Assistance Publique Hôpitaux de Paris), Paris, and in the Burn Unit of Edouard Herriot Hospital, Lyon, France. The study was approved by our local ethic committee (PRONOBUrn study, comité de protection des personnes IV, St-Louis Hospital; Institutional Review Board 00003835, protocol 2013/17NICB). All patients admitted to our intensive care burn units (ICBU) between April 2014 and April 2016 and meeting the inclusion criteria were included. Inclusion criteria were the following:

- A total body surface area [TBSA] burned > 15%
- Admission in the ICBU within the 72 h following burn injury

- No decision to withdraw life support
- Available plasma sample at admission

Outcome

The endpoints were 90-day mortality, circulatory failure in the first 48 h, and AKI.

Measurements

The following data have been collected: sex, age, body mass index (BMI), TBSA, full-thickness body surface area (BSA) burned, mechanism of injury and patients' characteristics, Abbreviated Burn Severity Index (ABS1) [9], Unit Burn Standard (UBS) [10], Sequential Organ Failure Assessment (SOFA) score [11], 28- and 90-day mortality, and AKI. Patients were resuscitated according to the Intensive Care Burn Unit resuscitation protocol [12]. A transthoracic or transesophageal echocardiography was performed at admission of patients according to the decision of the physician in charge. When performed, left ventricular ejection fraction (LVEF) was visually evaluated and systolic cardiac dysfunction was defined by a LVEF < 50% [13]. Circulatory failure was defined as a need for hemodynamic support with inotrope and/or a vasopressor (i.e., dobutamine, epinephrine, or norepinephrine) despite appropriate fluid resuscitation in the first 48 h. We choose this time frame to identify circulatory failure related to burn injury (as opposed to sepsis or surgical procedures which occur later during the course of burn injuries). AKI was defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria [14] during the first 7 days post admission. Admission serum creatinine e ($\text{Screat}_{\text{admin}}$) was used as baseline Screat.

Venous blood samples were collected at admission and at day 3 in tubes containing ethylene-diamine-tetra-acetic acid. After centrifugation, plasma was kept frozen at –80 °C until assayed. DPP3 was measured using the recently developed DPP3 luminescence immunoassay [15].

Statistical analysis

Values are expressed as medians and interquartile ranges (IQR) or counts and percentages as appropriate. Group comparisons of continuous variables were performed using Kruskal-Wallis test. Categorical data were compared using Pearson's chi-squared test for count data. DPP3 data was log-transformed. Cox proportional-

hazards regression was used to analyze the effect of risk factors on survival in uni- and multivariable analyses, and logistic regression was used for dichotomous endpoints. In both cases, to demonstrate independence from other variables, the added value of DPP3 on top of these was evaluated based on the likelihood ratio chi-squared test for nested models. The concordance index (C index or AUC) is given as an effect measure for uni- and multivariable models. For multivariable models, a bootstrap-corrected version of the C index is given. For continuous variables, hazard ratios (HR) or odds ratios (OR), as appropriate, were standardized to describe the HR/OR for a change of one IQR. HR (Cox regression) are used if time-to-event data is available; OR (logistic regression) are used if endpoints have event data (yes/no) only. Survival curves plotted by the Kaplan-Meier method were used for illustrative purposes. For dichotomous endpoints, receiver operating characteristic (ROC) curves were constructed for illustration. All statistical tests were 2-tailed and a two-sided *p*-value of 0.05 was considered for significance. The statistical analyses were performed using R version 3.4.3 (<http://www.r-project.org>, library rms, Hmisc, ROC) and Statistical Package for the Social Sciences (SPSS) version 22.0 (SPSS Inc., Chicago, Illinois, USA).

Results

Study population

From April 2014 to April 2016, 208 consecutive patients met the inclusion criteria; 55 patients had missing plasma at admission and were not included in the final analysis, resulting in 111 patients that were analyzed. The characteristics of the patients included in this study are summarized in Table 1. The median age was 48 (32.5–63) years, with a median TBSA of 35% (25–53.5) and median ABSI of 8 (7–11). All patients had a DPP3_{admin} measurement and 79 patients (71%) had DPP3_{Day3} (10 patients died before day 3 and 22 patients had missing measurements at day 3).

DPP3_{admin} and 90-day mortality

Thirty-six (32%) patients died before day 90. Median DPP3_{admin} was significantly higher in non-survivors versus survivors (53.3 ng/mL [IQR 28.8–103.5] versus 27.1 ng/mL [IQR 19.4–38.9]; *p* < 0.0001). We observed a step-wise increase in mortality among quartile groups of DPP3_{admin}, the patients in the highest quartile having the highest mortality (Fig. 1). There was no interaction between DPP3 value and TBSA (*p* = 0.7132) (Supplementary Figure 1). The C index of DPP3_{admin} for 90-day mortality was 0.734 (0.653–0.815, *p* < 0.0001, standardized HR 2.6 (1.9–3.6)). DPP3_{admin} added prognostic value on top of ABSI (added *chi*² 24.5, *p* < 0.0001), SOFA score at admission (SOFA_{admin}, added *chi*² 15.4, *p* <

0.0001), and lactate at admission (added *chi*² 11.7, *p* = 0.0006) to predict 90-day mortality (Fig. 2). Furthermore, adding DPP3_{Day3} to DPP3_{admin} provided added value to predict 90-day mortality (added *chi*² 5.6, *p* = 0.018; missing data at day 3 replaced with admission data). Patients with a high DPP3_{admin} that decreased at day 3 had a better prognosis than patients with high DPP3_{admin} and sustained DPP3_{Day3} (Fig. 3).

DPP3 and circulatory failure

Fifty-three (48%) patients had circulatory failure during the first 48 h (44 patients received norepinephrine, five patients received dobutamine + norepinephrine, 4 patients received epinephrine). DPP3_{admin} was significantly higher in patients with circulatory failure compared to patients without (39.2 ng/mL [IQR 25.9–76.1] versus 28.4 ng/mL [IQR 19.8–39.6]; *p* = 0.001) (Fig. 4 left panel). DPP3_{admin} was associated with circulatory failure with an AUC of 0.680 (0.581–0.778, *p* < 0.0001, standardized OR 2.8 (1.6–4.9)). DPP3_{admin} provided value on top of ABSI (added *chi*² 12.2, *p* = 0.0005), SOFA score at admission (SOFA_{admin}, added *chi*² 4.9, *p* = 0.0268), and lactate at admission (added *chi*² 6.9, *p* = 0.0086) to predict hemodynamic support in the first 48 h. There was no correlation between DPP3 and the volume administered on day 1 (*r* = 0.17, *p* = 0.07).

Fifty-nine patients (53%) had an echocardiography performed at admission. Among them, 10 (17%) patients had a systolic cardiac dysfunction. DPP3_{admin} was significantly higher in patients with systolic cardiac dysfunction compared to patients without (62.4 ng/mL [IQR 40.4–112.3] versus 29.3 ng/mL [IQR 22.4–45.1]; *p* < 0.0122) (Fig. 4 middle panel). The area under the ROC curve for DPP3_{admin} to predict systolic cardiac dysfunction was 0.753 (95%CI 0.582–0.925, *p* = 0.0054).

DPP3 and acute kidney injury

Thirty-five (32%) patients developed AKI during the first 7 days. DPP3_{admin} was significantly higher in patients with AKI compared to patients without (49.7 ng/mL [IQR 30.3–87.3] versus 27.6 ng/mL [IQR 19.4–41.4]; *p* = 0.001) (Fig. 4 right panel). DPP3_{admin} was associated with AKI with an AUC of 0.735 (0.641–0.829, *p* = 0.0005, standardized OR 2.3 (1.4–4.0)). DPP3_{admin} added value on top of ABSI (added *chi*² 9.4, *p* = 0.0022), SOFA score at admission (SOFA_{admin}, added *chi*² 14.3, *p* = 0.0002), but not on top of creatinine at admission (added *chi*² 0.3, *p* = 0.5954) to predict AKI.

Discussion

In this biomarker analysis of a prospective cohort, we observed that DPP3_{admin} was strongly associated with 90-day mortality, circulatory failure, and AKI in severely burned patients. Furthermore, adding DPP3_{admin} to

Table 1 Patients characteristics

Patient's characteristics	Total, N = 111	90-day survivors, N = 75	90-day non-survivors, N = 36	p
Sex, male—n (%)	71 (64)	51 (68)	20 (56)	0.2858
Age—year	48 [32.5–63]	42 [29–58]	56.5 [42–79]	0.0013
BMI—kg/m ²	25.2 [22.9–28.7]	25.1 [23–28.3]	25.7 [22.4–29.1]	0.9673
Medical history				
CIC—n (%)	3 (2.7)	2 (3)	1 (3)	1.0000
COPD—n (%)	3 (2.7)	2 (3)	1 (3)	1.0000
CKD—n (n)	5 (4.5)	1 (1)	4 (11)	0.0374
Chronic HBP—n (%)	25 (22.5)	12 (16)	13 (36)	0.0277
Psychiatric—n (%)	34 (30.6)	22 (29)	12 (33)	0.6668
Burn characteristics				
TBSA—%	35 [25–53.5]	32 [22–45]	57 [31–70]	< 0.0001
Deep burn BSA—%	21 [10–40]	17 [7–30]	42 [15–61]	0.0001
Inhalation injury—n (%)	54 (48.6)	28 (37)	26 (72)	0.0012
Characteristics during hospitalization				
Mechanic ventilation—n (%)	82 (73.9)	52 (69)	30 (83)	0.1799
DPP3 _{admin} (ng/mL)	30.6 [22.4–53.6]	27.1 [19.4–40.2]	53.3 [29.5–104]	< 0.0001
DPP3 _{day3} (ng/mL)	17.3 [11.8–25.2]	14.1 [11.5–20.6]	22.1 [16.6–30.8]	0.0102
Screat—μmol/L	72.5 [56.5–92]	70 [54.8–81.3]	90.5 [67.3–138.3]	0.0003
Lactate—mmol/L	3.5 [2.0–5.7]	2.7 [1.7–4.6]	5.2 [3.5–8]	< 0.0001
Bilirubin—mmol/L	14.0 [9.3–21.3]	12.9 [9–19.3]	18 [10.9–25.9]	0.0945
Platelet—G/L	250 [185–304]	236 [183–277]	279 [180–372]	0.3840
Length of hospitalization—days	90 [35.5–90]	41 [26–61]	18 [2–32.5]	< 0.0001
RRT—n (%)	24 (21.6)	5 (7)	28 (78)	< 0.0001
Severity scores				
SOFA	4 [1–7]	2 [0–4]	6.5 [3.3–9.8]	< 0.0001
ABSI	8 [7–11]	8 [6–9]	11 [9–13]	< 0.0001
SAPS2	33 [23–47]	28 [20–42]	47 [33–62]	< 0.0001
UBS	100 [52.5–166]	84 [45–132]	184 [86–249]	< 0.0001
Hemodynamic on admission				
Echocardiography, n (%)	59 (53)	33 (44)	26 (72)	0.0078
Systolic cardiac dysfunction, n (%)	10 (9)	2 (3)	8 (22)	0.0163
Circulatory failure, n (%)	53 (48)	24 (32)	29 (81)	< 0.0001
MAP in mmHg	79 [70–95]	84 [73–97]	73 [64–85]	0.0104
Volume of crystalloids at day 1	8250 [3700–15,000]	6700 [3300–12,800]	13,400 [6430–18,380]	0.0018
Volume of crystalloids at day 2	3000 [1000–5650]	2500 [1000–5150]	4000 [2000–7500]	0.1078

BMI body mass index, CIC chronic ischemic cardiopathy, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, HBP high blood pressure, TBSA total burn surface area, ECMO extracorporeal membrane oxygenation, Screat serum creatinine at admission, RRT renal replacement therapy, SOFA score simplified organ failure assessment, ABSI Abbreviated Burn Severity Index, UBS Unit Burn Standard, SAPS 2 The Simplified Acute Physiology Score

SOFA_{admin}, lactate_{admin}, or ABSI outperformed these prognostic factors to predict 90-day mortality. Serial measurements of DPP3 have improved the prediction of outcome compared to DPP3_{admin} alone.

While the prognosis of burn patients has improved, the mortality of most severe patients remains high with many patients dying from circulatory failure and multiple organ failure [16, 17]. Initial hemodynamic management has

long been considered critical in the treatment and prognosis of burn patients [18]. Burn injury is characterized by an initial hypodynamic state with low cardiac output due to hypovolemia followed by a hyperdynamic state with high cardiac output and low vascular resistance developing 12 to 24 h after the injury [1]. The severity of the distributive shock and occurrence of cardiac dysfunction may, however, vary greatly between




Fig. 1 Represents a survival Kaplan-Meier curve depending on $DPP3_{\text{admin}}$ quartiles (legend gives quartile ranges for $DPP3$ in nanograms/milliliter)

patients. The association between $DPP3$ levels, circulatory failure, and AKI is consistent with the current understanding of AKI in the critically ill, associating hemodynamic factors and inflammation/immune response [19, 20]. These results might also be expected in patients developing systemic inflammatory response from

different causes (e.g., sepsis, post-cardiopulmonary bypass, post-cardiac arrest, pancreatitis), and it should be further explored.

In the current study, $DPP3$ was strongly associated with mortality and hemodynamic failure, even after adjustment for classic markers of severity and prognosis.




Fig. 2 Represents unadjusted and adjusted (i.e., on Sequential Organ Failure Assessment-SOFA-OFA score or Abbreviated Burn Severity Index-ABSI) hazard ratio (HR) and/or odds ratio (OR) of $DPP3_{\text{admin}}$ value and outcomes (i.e., mortality, cardiac dysfunction, circulatory failure and acute kidney injury, AKI, respectively). Mortality $n = 111/36$ events, HR not adjusted HR = 2.6 (1.9–3.6); adjusted on SOFA score, HR = 2.2 (1.5–3.2); and adjusted on ABSI, HR = 2.6 (1.8–3.6), respectively. Circulatory failure, $n = 111/53$ events, OR not adjusted: OR = 2.8 (1.6–4.9); adjusted on SOFA score, HR = 2.1 (1.0–4.2) and adjusted on ABSI, HR = 2.8 (1.4–5.4), respectively. Cardiac dysfunction, $n = 59/10$ events, OR not adjusted: OR = 2.8 (1.2–6.4); adjusted on SOFA score, HR = 2.2 (0.96–5.0) and adjusted on ABSI, HR = 3.5 (1.3–9.2), respectively. Acute kidney injury (AKI) $n = 111/35$ events, OR not adjusted: OR = 2.3 (1.4–4.0); adjusted on SOFA score, HR = 1.7 (0.93–3.0); and adjusted on ABSI, HR = 2.2 (1.3–3.7), respectively




Fig. 3 Represents an illustration of the added value of DPP3_{day 3} using a cut point of 53.65 ng/mL at admission and day 3. Patients without DPP3 data at day 3 were left in their subgroup assigned to on day 1. High at admission and high at day 3 (HH): patients above 53.65 ng/mL at admission and at day 3; high at admission and low at day 3 (HL): patients above 53.65 ng/mL at admission and below 53.65 ng/mL at day 3; low at admission and high at day 3 (LH): patients below 53.65 ng/mL at admission and above 53.65 ng/mL at day 3; low at admission and low at day 3 (LL): Patients below 53.65 ng/mL at admission and on day 3. Cut point identified is the third quartile (53.65 ng/mL)

Recently, Deniau et al. observed an association between high plasmatic levels of DPP3 and high mortality and organ dysfunction in severe heart failure patients. Furthermore, I.V. administration of DPP3 rapidly deteriorated cardiac contraction in mice [21]. In an ancillary study of the OptimaCC study, Takagi et al. showed that high circulating DPP3 was associated with low cardiac

index, refractory shock, and high mortality in patients with cardiogenic shock [22].

The results of the present study have several potential implications for future research. First, the identification of patients with high plasma DPP3 may trigger cardiac function assessment. Second, high DPP3 levels at admission may help to select candidate patients for




Fig. 4 Represents median DPP3_{admin} between patients with and without circulatory failure in the first 48 h (left panel), between patients with or without systolic cardiac dysfunction at admission (middle panel), and between patients with or without acute kidney injury (right panel)

alternative vasopressor therapies, especially for infusion of angiotensin II [23, 24]. Angiotensin II has been found to be downregulated in some forms of septic shock associated with poor prognosis [25]. DPP3 cleaves angiotensin II and may, therefore, play a role in vasoplegic shock by reducing angiotensin II levels. Since angiotensin II is not easy to measure in clinical practice, DPP3 may represent a potential candidate biomarker for selecting patients most likely to respond to angiotensin II infusion. Third, pharmacological inhibition of DPP3 by a specific antibody has been shown to promptly restore and sustain cardiac contraction in mice [21] and might be a therapeutic option in burn patients with high DPP3. All these strategies are hypothesis and require exploration and validation in well-designed prospective human studies.

Our study has several limitations. First, the observational design of the present study does not allow us to conclude on the causality between DPP3 and mortality or organ dysfunction. Second, the study contains a relatively low number of patients, even though this is one of the largest cohort studies among critically ill burn patients with sufficient power to identify an association between the biomarker levels and outcomes. Thirdly, factors influencing DPP3 metabolism are unknown and will need further exploration in critically ill burn patients. Finally, only half of our patients had an echocardiography at admission, limiting the interpretation of the association between DPP3 levels and cardiac dysfunction.

Conclusion

Plasma DPP3 concentration at admission was associated with an increased risk of death, circulatory failure, and AKI in severely burned patients. Whether DPP3 plasma levels could identify patients who would respond to alternative hemodynamic support strategies, such as intravenous angiotensin II, should be explored.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s13054-020-02888-5>.

Additional file 1: Figure S1. represents interaction between Total Body Surface Area (TBSA) and DPP3_{admin} (TF 43 kb)

Additional file 2. Supplementary data Table 1. Patients characteristics according to TBSA (Total burn surface area).

Abbreviations

DPP3: Dipeptidyl peptidase-3; AKI: Acute kidney injury; ICBU: Intensive care burn unit; TBSA: Total body surface area burn; BMI: Body mass index; BSA: Body surface area; ABSI: Abbreviated Burn Severity Index; UBS: Unit Burn Standard; SOFA: Sequential Organ Failure Assessment; LVEF: Left ventricular ejection fraction; KDIGO: Kidney Disease: Improving Global Outcomes; IQR: Interquartile range; HR: Hazard ratio; OR: Odds ratio; ROC: Receiver operator characteristics

Acknowledgments

The paramedical staff of Burn Intensive Care unit of Saint-Louis hospital for their active participation to the protocol. We thank the Clinical Research Assistants, Marie-Céline Fournier, and Elisabeth Cerrato from the joint research unit HCL/bioMérieux for the technical assistance with the samples.

Authors' contributions

FD collected the data, contributed to the interpretation of the data, and drafted the manuscript. AP collected the data, contributed to the interpretation of the data, and drafted the manuscript. JA collected the data, contributed to the interpretation of the data, and drafted the manuscript. LFP collected the data, contributed to the interpretation of the data, and drafted the manuscript. MCo collected the data, contributed to the interpretation of the data, and drafted the manuscript. MCh collected the data, contributed to the interpretation of the data, and drafted the manuscript. KS performed DPP3 measurements, contributed to the interpretation of the data, and drafted the manuscript. OH performed analysis and contributed to the interpretation of the data, and drafted the manuscript. MJ collected the data, contributed to the interpretation of the data, and drafted the manuscript. AF collected the data, contributed to the interpretation of the data, and drafted the manuscript. HO collected the data, contributed to the interpretation of the data, and drafted the manuscript. AC collected the data, contributed to the interpretation of the data, and drafted the manuscript. MB collected the data, contributed to the interpretation of the data, and drafted the manuscript. LG collected the data, contributed to the interpretation of the data, and drafted the manuscript. BD collected the data, contributed to the interpretation of the data, and drafted the manuscript. AM conceived the study, contributed to the interpretation of the data, and drafted the manuscript. BF collected the data, contributed to the interpretation of the data, and drafted the manuscript. JT collected the data, contributed to the interpretation of the data, and drafted the manuscript. ML conceived the study, contributed to the interpretation of the data, and drafted the manuscript. The authors read and approved the final manuscript.

Funding

This study was supported by a grant from the "Association des Gueules cassées" to Matthieu Legrand. Measurement of DPP3 was funded by 4TEEN4 Pharmaceuticals GmbH.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The study protocol was approved by our local research ethical committee (Comité de Protection des Personnes 2013/17NICB).

Consent for publication

Not applicable.

Competing interests

FD has received research grants from the French ministry of health, Société française d'anesthésie réanimation, European Society of Intensive Care Medicine, and lecture fees Sedana medical.

JA has no conflict of interest.

MCo has no conflict of interest.

MCh has no conflict of interest.

KS and OH are employed by 4TEEN4 Pharmaceuticals GmbH, a company which holds patent rights in and commercializes the DPP3 assay.

MJ has no conflict of interest.

AF has no conflict of interest.

HO has no conflict of interest.

AC has no conflict of interest.

MB has no conflict of interest.

LG has no conflict of interest.

BD received research grant from 4TEEN4 Pharmaceuticals GmbH.

AM has received speaker's honoraria from Novartis, Orion, and Servier and fees as a member of the advisory board and/or steering committee from Cardiorentis, Adrenoméd, sphingotec, Sanofi, Roche, Abbott, and Bristol-Myers Squibb.

BS has no conflict of interest.

JT is employed by Biomerieux.

ML has received research grants from the French ministry of health, lecture fees from Baxter, and Fresenius and research support from Sphingotec.

Author details

¹Department of Anesthesiology and Critical Care and Burn Unit, AP-HP, GH St-Louis-Lariboisière, Paris, France. ²University Paris Diderot, Paris, France. ³UMR INSERM 942, Institut National de la Santé et de la Recherche Médicale (INSERM), F-CRIN INICRCT network, Paris, France. ⁴Department of Anesthesiology and Critical Care, Burn Center Pierre Colson, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France. ⁵4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany. ⁶EA 7426 Pathophysiology of Injury-induced Immunosuppression, University of Lyon1-Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, Lyon, France. ⁷Department of Anesthesia and Perioperative Care, UCSF Medical Center, University of California, 500 Parnassus Avenue MUE416, Box 0648, San Francisco, CA 94143, USA.

Received: 20 February 2020 Accepted: 13 April 2020

Published online: 22 April 2020

References

- Soussi S, Dépret F, Benyamina M, Legrand M. Early hemodynamic management of critically ill burn patients. *Anesthesiology*. 2018;129:583–9.
- Soussi S, Deniau B, Ferry A, Levé C, Benyamina M, Maurel V, et al. Low cardiac index and stroke volume on admission are associated with poor outcome in critically ill burn patients: a retrospective cohort study. *Ann Intensive Care*. 2016;6:87.
- Soussi S, Taccori M, De Tymowski C, Dépret F, Chaussard M, Fratani A, et al. Risk factors for acute mesenteric ischemia in critically ill burns patients—a matched case-control study. *Shock*. 2019;51:153–60.
- Bak Z, Sjöberg F, Eriksson O, Steinvall I, Janerot-Sjöberg B. Cardiac dysfunction after burns. *Burns*. 2008;34:603–9.
- Zhan H, Yamamoto Y, Shumiya S, Kunitatsu M, Nishi K, Ohkubo I, et al. Peptidases play an important role in cataractogenesis: an immunohistochemical study on lenses derived from Shumiya cataract rats. *Histochem J*. 2001;33:511–21.
- Prajapati SC, Chauhan SS. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter: dipeptidyl peptidase III. *FEBS J*. 2011;278: 3256–76.
- Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, et al. Novel therapeutic role for dipeptidyl peptidase III in the treatment of hypertension. *Hypertension*. 2016;68:630–41.
- Dale CS, Pagano R de L, Rioli V. Hemopressin: a novel bioactive peptide derived from the α1-chain of hemoglobin. p. 2. <https://doi.org/10.1590/s0074-02762005000900017>.
- Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. *Ann Emerg Med*. 1982;11:260–2.
- Bull JP, Squire JR. A study of mortality in a burns unit: standards for the evaluation of alternative methods of treatment. *Ann Surg*. 1949;130:160.
- Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. *Intensive Care Med*. 1996;22:707–10.
- Soussi S, Dépret F, Benyamina M, Legrand M. *Anesthesiology*. 2018;129(3): 583–9. <https://doi.org/10.1097/ALN.0000000000002314>.
- Rich S, Sheikh A, Gallastegui J, Kondos GT, Mason T, Lam W. Determination of left ventricular ejection fraction by visual estimation during real-time two-dimensional echocardiography. *Am Heart J*. 1982;104:603–6.
- Kellum JA, Lameire N, For the KDIGO AKI guideline work group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). *Crit Care*. 2013;17:204.
- Rehfeld L, Funk E, Jha S, Macheroux P, Melander O, Bergmann A. Novel methods for the quantification of dipeptidyl peptidase 3 (DPP3) concentration and activity in human blood samples. *J Appl Lab Med*. 2019; 3:943–53.
- Greenhalgh DG. Management of burns. *N Engl J Med*. 2019;380:2349–59.
- Jeschke MG, Pinto R, Kraft R, Nathens AB, Finnerty CC, Gamelli RL, et al. Morbidity and survival probability in burn patients in modern burn care. *Crit Care Med*. 2015;43:808–15.
- Legrand M, Guttormsen AB, Berger MM. Ten tips for managing critically ill burn patients: follow the RASTAFARI! *Intensive Care Med*. 2015;41:1107–9.
- Ronco C, Bellomo R, Kellum JA. Acute kidney injury. *Lancet Lond Engl*. 2019; 394:1949–64.
- Wong BT, Chan MJ, Glassford NJ, Mårtensson J, Bion V, Chai SY, et al. Mean arterial pressure and mean perfusion pressure deficit in septic acute kidney injury. *J Crit Care*. 2015;30:975–81.
- Deniau B, Rehfeld L, Santos K, Dieneilt A, Azibani F, Sadoune M, Kounde PR, Samuel JL, Tolpannen H, Lassus J, Harjola VP, Vodovar N, Bergmann A, Hartmann O, Mebazaa A, Blet A. *Eur J Heart Fail*. 2020;22(2):290–9. <https://doi.org/10.1002/ejhf.1601>.
- Takagi K, Blet A, Levy B, Deniau B, Azibani F, Feliot E, Bergmann A, Santos K, Hartmann O, Gayat E, Mebazaa A, Kimmoun A. *Eur J Heart Fail*. 2020;22(2): 279–86. <https://doi.org/10.1002/ejhf.1600>.
- Chow JH, Abuelkasem E, Sankova S, Henderson RA, Mazzeff MA, Tanaka KA. Reversal of vasodilatory shock: current perspectives on conventional, rescue, and emerging vasoactive agents for the treatment of shock. *Anesth Analg*. 2020;130:15–30.
- Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. *N Engl J Med*. 2017; 377:419–30.
- Wakefield BJ, Sacha GL, Khanna AK. Vasodilatory shock in the ICU and the role of angiotensin II. *Curr Opin Crit Care*. 2018;24:277–85.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

